Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Axsome Therapeutics (AXSM) Non-Current Assets (2022 - 2025)

Historic Non-Current Assets for Axsome Therapeutics (AXSM) over the last 4 years, with Q3 2025 value amounting to $103.9 million.

  • Axsome Therapeutics' Non-Current Assets rose 2618.62% to $103.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $392.5 million, marking a year-over-year increase of 1656.66%. This contributed to the annual value of $83.4 million for FY2024, which is 64.19% down from last year.
  • According to the latest figures from Q3 2025, Axsome Therapeutics' Non-Current Assets is $103.9 million, which was up 2618.62% from $103.2 million recorded in Q2 2025.
  • Over the past 5 years, Axsome Therapeutics' Non-Current Assets peaked at $103.9 million during Q3 2025, and registered a low of $1.7 million during Q1 2022.
  • Its 4-year average for Non-Current Assets is $83.1 million, with a median of $85.2 million in 2024.
  • As far as peak fluctuations go, Axsome Therapeutics' Non-Current Assets surged by 479673.96% in 2023, and later tumbled by 757.51% in 2024.
  • Axsome Therapeutics' Non-Current Assets (Quarter) stood at $85.8 million in 2022, then decreased by 2.17% to $84.0 million in 2023, then decreased by 0.64% to $83.4 million in 2024, then rose by 24.54% to $103.9 million in 2025.
  • Its Non-Current Assets stands at $103.9 million for Q3 2025, versus $103.2 million for Q2 2025 and $102.0 million for Q1 2025.